Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0105 | 0 | 0.5 |
Trichomonas vaginalis | cdc25b, putative | 0.0105 | 0 | 0.5 |
Trichomonas vaginalis | mitotic inducer phosphatase CDC25, putative | 0.0105 | 0 | 0.5 |
Trichomonas vaginalis | m-phase inducer phosphatase, putative | 0.0105 | 0 | 0.5 |
Trichomonas vaginalis | mitotic inducer phosphatase CDC25, putative | 0.0105 | 0 | 0.5 |
Trichomonas vaginalis | m-phase inducer phosphatase, putative | 0.0105 | 0 | 0.5 |
Trypanosoma cruzi | Emopamil binding protein, putative | 0.0849 | 1 | 0.5 |
Trypanosoma cruzi | Emopamil binding protein, putative | 0.0849 | 1 | 0.5 |
Trichomonas vaginalis | mitotic inducer phosphatase CDC25, putative | 0.0105 | 0 | 0.5 |
Entamoeba histolytica | rodhanase-like domain containing protein | 0.0105 | 0 | 0.5 |
Onchocerca volvulus | 0.0849 | 1 | 1 | |
Trypanosoma brucei | Emopamil binding protein, putative | 0.0849 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0105 | 0 | 0.5 |
Schistosoma mansoni | m-phase inducer phosphatase(cdc25) | 0.0105 | 0 | 0.5 |
Echinococcus granulosus | m phase inducer phosphatasecdc25 | 0.0105 | 0 | 0.5 |
Trypanosoma cruzi | 3-Beta-hydroxysteroid-delta(8), delta(7)-isomerase, putative | 0.0849 | 1 | 0.5 |
Brugia malayi | Rhodanese-like domain containing protein | 0.0105 | 0 | 0.5 |
Entamoeba histolytica | rodhanase-like domain containing protein | 0.0105 | 0 | 0.5 |
Leishmania major | 3-Beta-hydroxysteroid-delta(8), delta(7)-isomerase, putative | 0.0849 | 1 | 0.5 |
Trichomonas vaginalis | cdc25c, putative | 0.0105 | 0 | 0.5 |
Trypanosoma cruzi | 3-Beta-hydroxysteroid-delta(8), delta(7)-isomerase, putative | 0.0849 | 1 | 0.5 |
Entamoeba histolytica | rodhanase-like domain containing protein | 0.0105 | 0 | 0.5 |
Echinococcus multilocularis | m phase inducer phosphatase(cdc25) | 0.0105 | 0 | 0.5 |
Trichomonas vaginalis | cdc25b, putative | 0.0105 | 0 | 0.5 |
Brugia malayi | Rhodanese-like domain containing protein | 0.0105 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.